Annual CFF
-$76.06 M
+$165.34 M+68.49%
01 December 2023
Summary:
Sinovac Biotech annual cash flow from financing activities is currently -$76.06 million, with the most recent change of +$165.34 million (+68.49%) on 01 December 2023. During the last 3 years, it has fallen by -$668.63 million (-112.84%). SVA annual CFF is now -112.84% below its all-time high of $592.57 million, reached on 31 December 2020.SVA Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
N/A
01 June 2024
Summary:
Sinovac Biotech quarterly cash flow from financing activities is not available.SVA Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
N/A
01 June 2024
Summary:
Sinovac Biotech TTM cash flow from financing activities is not available.SVA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SVA Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -112.8% | - | - |
| 5 y5 years | -218.5% | - | - |
SVA Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -112.8% | +96.0% | ||||
| 5 y | 5 years | -112.8% | +96.0% | ||||
| alltime | all time | -112.8% | +96.0% |
Sinovac Biotech Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | -$76.06 M(-68.5%) | - | - |
| Dec 2022 | -$241.40 M(-87.3%) | - | - |
| Dec 2021 | -$1.90 B(-420.1%) | - | - |
| Dec 2020 | $592.57 M(>+9900.0%) | $541.64 M(+2250.0%) | $592.57 M(+1004.0%) |
| Sept 2020 | - | $23.05 M(+8.6%) | $53.67 M(+75.0%) |
| June 2020 | - | $21.23 M(+219.4%) | $30.67 M(+221.9%) |
| Mar 2020 | - | $6.65 M(+141.4%) | $9.53 M(+448.5%) |
| Dec 2019 | $1.74 M(-97.3%) | $2.75 M(+6156.8%) | $1.74 M(-113.5%) |
| Sept 2019 | - | $44.00 K(-48.2%) | -$12.90 M(-117.7%) |
| June 2019 | - | $85.00 K(-107.4%) | $72.69 M(+4.5%) |
| Mar 2019 | - | -$1.15 M(-90.4%) | $69.58 M(+8.4%) |
| Dec 2018 | $64.18 M(-4882.4%) | -$11.88 M(-113.9%) | $64.18 M(-15.6%) |
| Sept 2018 | - | $85.64 M(-2930.9%) | $76.06 M(-894.5%) |
| June 2018 | - | -$3.02 M(-53.8%) | -$9.57 M(+46.2%) |
| Mar 2018 | - | -$6.55 M(-147.2%) | -$6.55 M(-123.6%) |
| Dec 2017 | -$1.34 M(-104.8%) | - | - |
| Dec 2016 | $27.78 M(-214.8%) | $13.88 M(+69.1%) | $27.78 M(+131.8%) |
| Sept 2016 | - | $8.21 M(-265.0%) | $11.98 M(-595.0%) |
| June 2016 | - | -$4.97 M(-146.6%) | -$2.42 M(-150.3%) |
| Mar 2016 | - | $10.67 M(-655.3%) | $4.81 M(-119.9%) |
| Dec 2015 | -$24.20 M(-555.8%) | -$1.92 M(-69.0%) | -$24.20 M(-15.3%) |
| Sept 2015 | - | -$6.20 M(-374.1%) | -$28.57 M(+145.0%) |
| June 2015 | - | $2.26 M(-112.3%) | -$11.66 M(-29.2%) |
| Mar 2015 | - | -$18.34 M(+191.3%) | -$16.46 M(-410.0%) |
| Dec 2014 | $5.31 M(-63.2%) | -$6.29 M(-158.8%) | $5.31 M(-51.6%) |
| Sept 2014 | - | $10.71 M(-521.9%) | $10.97 M(+193.5%) |
| June 2014 | - | -$2.54 M(-174.0%) | $3.74 M(-62.2%) |
| Mar 2014 | - | $3.43 M(-644.6%) | $9.89 M(-31.4%) |
| Dec 2013 | $14.42 M | -$630.00 K(-118.1%) | $14.42 M(-34.5%) |
| Sept 2013 | - | $3.48 M(-3.8%) | $22.03 M(+10.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2013 | - | $3.61 M(-54.6%) | $19.88 M(-4.6%) |
| Mar 2013 | - | $7.96 M(+14.0%) | $20.84 M(+20.3%) |
| Dec 2012 | $17.33 M(+2727.1%) | $6.98 M(+424.5%) | $17.33 M(+72.2%) |
| Sept 2012 | - | $1.33 M(-70.9%) | $10.07 M(-8.8%) |
| June 2012 | - | $4.57 M(+2.8%) | $11.04 M(+52.6%) |
| Mar 2012 | - | $4.45 M(-1664.3%) | $7.23 M(+1080.1%) |
| Dec 2011 | $613.00 K(-98.9%) | -$284.40 K(-112.3%) | $613.00 K(-93.8%) |
| Sept 2011 | - | $2.30 M(+200.4%) | $9.95 M(+38.2%) |
| June 2011 | - | $766.60 K(-135.3%) | $7.20 M(-194.9%) |
| Mar 2011 | - | -$2.17 M(-124.0%) | -$7.59 M(-113.0%) |
| Dec 2010 | $58.19 M(+999.5%) | $9.05 M(-2117.5%) | $58.19 M(+26.3%) |
| Sept 2010 | - | -$448.70 K(-96.8%) | $46.06 M(+13.4%) |
| June 2010 | - | -$14.02 M(-122.0%) | $40.60 M(-42.6%) |
| Mar 2010 | - | $63.61 M(-2163.0%) | $70.68 M(+1235.4%) |
| Dec 2009 | $5.29 M(-36.4%) | -$3.08 M(-47.8%) | $5.29 M(-51.8%) |
| Sept 2009 | - | -$5.90 M(-136.8%) | $10.98 M(-29.7%) |
| June 2009 | - | $16.06 M(-1002.0%) | $15.62 M(-4873.5%) |
| Mar 2009 | - | -$1.78 M(-168.3%) | -$327.20 K(-103.9%) |
| Dec 2008 | $8.32 M(+49.5%) | $2.61 M(-306.0%) | $8.32 M(+45.6%) |
| Sept 2008 | - | -$1.27 M(-1229.6%) | $5.71 M(-18.1%) |
| June 2008 | - | $112.00 K(-98.4%) | $6.98 M(+1.6%) |
| Mar 2008 | - | $6.87 M | $6.87 M |
| Dec 2007 | $5.56 M(+39.7%) | - | - |
| Dec 2006 | $3.98 M(-64.3%) | - | - |
| Dec 2005 | $11.14 M(+93.0%) | - | - |
| Dec 2004 | $5.78 M(+62.2%) | - | - |
| Dec 2003 | $3.56 M(+3707.5%) | - | - |
| Apr 2002 | $93.50 K(-76.5%) | - | - |
| Apr 2001 | $398.60 K(-19.5%) | - | - |
| Apr 2000 | $495.00 K | - | - |
FAQ
- What is Sinovac Biotech annual cash flow from financing activities?
- What is the all time high annual CFF for Sinovac Biotech?
- What is the all time high quarterly CFF for Sinovac Biotech?
- What is the all time high TTM CFF for Sinovac Biotech?
What is Sinovac Biotech annual cash flow from financing activities?
The current annual CFF of SVA is -$76.06 M
What is the all time high annual CFF for Sinovac Biotech?
Sinovac Biotech all-time high annual cash flow from financing activities is $592.57 M
What is the all time high quarterly CFF for Sinovac Biotech?
Sinovac Biotech all-time high quarterly cash flow from financing activities is $541.64 M
What is the all time high TTM CFF for Sinovac Biotech?
Sinovac Biotech all-time high TTM cash flow from financing activities is $592.57 M